TABLE 5

Impact of DAA on coadministered HIV drug exposure (AUC)

Data are given in percentages.

ARV AgentSMPSOFDCVLDV/SOFOBV/PTV/DSV/rGZR/EBRSOF/VELSOF/VEL/VOXGLE/PIB
GZREBR
NRTI
 ABCb
 FTCbbb
 3TC
 TAF (10 mg, boosted)b,db,db,db,d
 TAF (25 mg, nonboosted)↑52–57b
 TDF (boosted regimen)↔, ↑50b,cb,d↔, ↑39b,c↑39b,c
 TDF (nonboosted regimen)ab↑98aa↑40–↑81bb
Protease inhibitor
 ATVb,ca,c↑43a,ca,cb,c
 DRVa,ca,cb,c↓24,a,e ↔,a,f ↑34a,ga,c,ha,c,hb,cb,cb,c
 LPVa,ca,c a,ca,ci
Entry/integrase inhibitor
 BICbb
 DTG33a↑38a
 EVGb,dbb,db,db,d
 RALa↑43dab↑47a
Non-NRTI
 EFV (600 mg daily)aaab
 RPV (25 mg daily)a↑225aabb↑84a
Pharmacokinetic enhancers (boosters)
 COBI↑53↑49b↑50
 RTVb↑45↑87
  • BIC, bictegravir; DCV, daclatasvir; DSV, dasabuvir; EBR, elbasvir; GLE, glecaprevir; GZR, grazoprevir; LDV, ledipasvir; OBV, ombitasvir; PIB, pibrentasvir; PTV, paritaprevir; RTV or/r, ritonavir; SMP, simeprevir; SOF, sofosbuvir; VEL, velpatasvir; VOX, voxilaprevir. ↑: increase in exposure; ↓: decrease in exposure; ↔: no change; —: data not available.

  • a HIV drug tested as a single agent.

  • b HIV drug tested as part of antiretroviral therapy regimen.

  • c Boosted with 100 mg RTV daily.

  • d Boosted with 150 mg COBI daily.

  • e 800 mg DRV daily AM plus OBV/PTV/DSV/r AM versus 800 mg DRV daily AM plus 100 mg RTV daily AM.

  • f 600 mg DRV twice daily AM/PM plus OBV/PTV/DSV/r AM plus 100 mg RTV daily PM versus 600 mg DRV twice daily AM/PM plus 100 mg RTV twice daily AM/PM.

  • g OBV/PTV/DSV/r AM plus 800 mg DRV daily PM plus 100 mg RTV daily PM versus 800 mg DRV daily PM plus 100 mg RTV daily PM.

  • h 600/100 mg twice daily.

  • i 800/200 mg daily.